(CercleFinance.com) – OSE Immunotherapeutics reported on Monday ‘very promising’ first results concerning a phase 1/2 clinical trial evaluating its monoclonal antibody in patients with solid tumors.
According to the biotech, these data showed first signs of effectiveness in the first 13 patients included, presenting eight types of tumor, whether they were treated at the dose of 100 and 300 mg every three weeks or at the dose of 600 mg every six weeks.
In detail, three responses were reported in 11 patients who had at least one post-inclusion tumor assessment, including a partial response in a patient with hepatocellular carcinoma (81% tumor reduction) after a single dose of 300 mg. .
Two partial responses, not yet confirmed, were also observed at a dose of 600 mg, one in an anal squamous cell carcinoma (46% tumor reduction) and the other in an undifferentiated pleomorphic sarcoma (46% tumor reduction). 33%).
In a press release, OSE mentions initial ‘positive’ results which are considered ‘encouraging’ with a view to continuing the clinical development of OSE-279 as a monotherapy in pre-identified niche indications affecting cancers with high medical need.
“This product could also be explored in combination with other OSE drug candidates or with external active ingredients, opening the way to potential new partnerships,” explains the biotechnology company.
OSE-279 is a humanized anti-PD1 monoclonal antibody that blocks both PD1 ligands overexpressed by tumor cells and the tumor microenvironment, while targeting other novel immunotherapy targets.
The results of this trial were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics which closed yesterday in Boston.
Listed on the Paris Stock Exchange, OSE Immunotherapeutics shares rose by almost 10% on Monday morning in early trading following this information.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Are you following this action?
Receive all the information on OSE IMMUNO in real time: